To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Nebivolol is a highly cardioselective vasodilatory beta1 receptor blocker used in treatment of hypertension. In most countries, this medication is available only by prescription.
Additional recommended knowledge
Mylan Laboratories licensed the U.S. and Canadian rights to nebivolol from Janssen Pharmaceutica N.V. in 2001. Nebivolol is already registered and successfully marketed in more than 50 other countries outside of North America. It is marketed under the brand name Nebilet. Nebivolol is manufactured by Forest Laboratories, Inc. In India, Nebivolol is available as Nebicard-5 (Torrent), Nubeta (Nicholas Piramal) and Nebipill (Alkem Mediva) reported by Ashok Mishra. In Greece and Italy, Nebivolol is marketed under the name Lobivon from Menarini pharmaceutical.
On December 18, 2007, Mylan and Forest Laboratories received final approval for nebivolol in the US, which is marketed under the tradename Bystolic®.
Adverse Drug Reactions
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Nebivolol". A list of authors is available in Wikipedia.|